Abstract
The US FDA granted accelerated approval to pralsetinib for the treatment of adult patients with metastatic RET fusion-positive non-small cell lung cancer.
MeSH terms
-
Adult
-
Antineoplastic Agents / therapeutic use*
-
Carcinoma, Non-Small-Cell Lung / drug therapy*
-
Carcinoma, Non-Small-Cell Lung / genetics
-
Carcinoma, Non-Small-Cell Lung / pathology
-
Drug Approval*
-
Gene Fusion*
-
Humans
-
Lung Neoplasms / drug therapy*
-
Lung Neoplasms / genetics
-
Lung Neoplasms / pathology
-
Proto-Oncogene Proteins c-ret / genetics*
-
Pyrazoles / adverse effects
-
Pyrazoles / therapeutic use*
-
Pyridines / adverse effects
-
Pyridines / therapeutic use*
-
Pyrimidines / adverse effects
-
Pyrimidines / therapeutic use*
-
United States
-
United States Food and Drug Administration
Substances
-
Antineoplastic Agents
-
Pyrazoles
-
Pyridines
-
Pyrimidines
-
pralsetinib
-
Proto-Oncogene Proteins c-ret
-
RET protein, human